206533-18-8Relevant academic research and scientific papers
Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors
Mao, Qing,Dai,Xu, Gaoyang,Su, Yu,Zhang, Bing,Liu, Dan,Wang, Shaojie
, (2019)
In our previous study, we reported a series of 1-hydroxy-2-phenyl-1H-imidazole-5-carboxylic acid derivatives that presented excellent in vitro xanthine oxidase (XO) inhibitory potency. To further investigate the structure-activity relationships of these compounds, the imidazole ring was transformed to a pyrimidine ring to design 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acids (8a-8j), 2-(4-alkoxy-3-cyano)phenyl-4-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acids (9c, 9e, 9j, 9l) and 2-(4-alkoxy-3-cyano)phenyl-6-imino-1,6-dihydropyrimidine-5-carboxylic acids (10c, 10e, 10j, 10l). These compounds exhibited remarkable in vitro XO inhibitory potency with IC50 values ranging from 0.0181 μM to 0.5677 μM. Specifically, compounds 10c and 10e, with IC50 values of 0.0240 μM and 0.0181 μM, respectively, emerged as the most potent XO inhibitors, and their potencies were comparable to that of febuxostat. Structure-activity relationship analysis revealed that the methyl group at 4-position of pyrimidine ring could damage the potency, and the XO inhibitory potency was maintained when carbonyl group was changed to an imino group. Lineweaver-Burk plot analysis revealed that the representative compound 10c acted as a mixed-type inhibitor. A potassium oxonate induced hyperuricemia model in rats was chosen to further confirm the hypouricemic effect of compound 10c, and the results showed that compound 10c (5 mg/kg) was able to significantly lower the serum uric acid level. Furthermore, in acute oral toxicity study, no sign of toxicity was observed when the mice were administered with a single 2000 mg/kg oral dose of compound 10c. These results suggested that compound 10c was a potent and promising uric acid-lowing agent for the treatment of hyperuricemia.
Preparation method and use of 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative
-
Paragraph 0076-0077; 0089-0090, (2019/09/14)
The invention belongs to the technical field of medicines, and relates to a preparation method and a use of a 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative. The invention provides the 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative represented by general formula I, or a pharmaceutically acceptable salt, an isomer, a polymorph and a medicinal solvate thereof, and further provides an intermediate for preparing the 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative or the pharmaceutically acceptable salt thereof. The structure of the intermediate is representedby general formula II, III or IV; and in the formulas, R, R and R are as defined in claims and the description.
A facile one-pot synthesis of 4-alkoxy-1,3-benzenedicarbonitrile
Hasegawa, Masaichi
, p. 857 - 864 (2007/10/03)
2-(3-Cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxlic acid (TEI-6720) was prepared. The introduction of cyano group to 4-nitrobenzonitrile with KCN in dry DMSO followed by quenching with alkyl halide afforded the key intermediates, 4-alkoky-1,3-benzenedicarbonitriles, in good yield. The reaction was completed in dry DMSO, while no reaction occurred in dry DMF. This observation can be suggested by the participation of DMSO in the reaction.
